Surgery Partners Investigation Overview
BFA Law is investigating the going private merger whereby Surgery Partners, Inc. (NADAQ: SGRY) is being taken private by Bon Secours Mercy Health, Inc. Surgery Partners is incorporated in Delaware.
If you are a current Surgery Partners shareholder, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
Why is the Surgery Partners Transaction being Investigated?
In the October 26, 2026 announcement of the merger, Surgery Partners disclosed that it was being taken private by Bon Secours Mercy Health, Inc., for a price of $23.50 per share. At the same time, the company disclosed that Bain Capital would be rolling over its equity into the post-merger entity. Bain Capital currently owns 39% of the company’s outstanding shares.
Surgery Partners has reported that the decision to enter into the merger was approved by a special committee of its board of directors, and the merger is conditioned on the majority approval of the minority stockholders. While Bain Capital’s ownership of the enterprise will continue, public stockholders have no opportunity to continue owning Surgery Partners after the merger.
BFA is investigating whether the terms of the merger comply with Delaware law, including whether Bain Capital’s self-interest in the merger caused related breaches of fiduciary duty, and whether the per share price is a fair price for the public stockholders’ shares of Surgery Partners stock.
How Do I Submit My Information?
If you are a current holder of Surgery Partners stock, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
You can also contact:
Adam McCall
adam@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
